Explore the complete list of our presses below (Page 17 of 27):
FDA approves ZORYVE® 0.05% cream for mild to moderate atopic dermatitis in children aged 2–5, offering a safe, non-steroidal treatment option.
Roche’s cobas BV/CV assay earns CE Mark, enabling precise detection of bacterial vaginosis and candida vaginitis using a single streamlined test.
EU approves Gazyva/Gazyvaro plus MMF for active lupus nephritis, backed by strong REGENCY data showing superior renal response and disease control.
Praxis announces positive relutrigine and vormatrigine data showing rapid, durable seizure reduction with strong safety ahead of FDA discussions.
Three-year STARGLO results show Columvi plus GemOx significantly improves survival in R/R DLBCL, supporting its global guideline-recommended use.
Agios reports the FDA has not yet ruled on its mitapivat sNDA for thalassemia, with review ongoing as labeling and REMS materials are finalized.
Howard Liang steps down as Tessera’s President & CFO; Kathy Bergsteinsson appointed CFO to support Gene Writing™ platform growth.
Novo Nordisk acquires Akero for $4.7B, offering $54/share cash and $6/share CVR for EFX in MASH cirrhosis, expanding its liver disease pipeline.
Alejandro Weinstein becomes Pluri’s Chairman as the company raises $2.5M via private placement to support growth and cell-based technology initiatives.
Pharma Project & Portfolio Management Conference 2026 in Goa unites industry leaders to master strategy, governance, execution, and digital transformation.
The 5th Drug Safety Symposium 2026 returns to Dubai, uniting regulators and pharma leaders to advance pharmacovigilance and patient safety in the Middle East.
Remarkable Women Camaraderie 2026 & Awards debuts in Goa, celebrating women’s leadership, mentorship, entrepreneurship, and empowerment.
Han Lee and Martin Murphy join Century Therapeutics’ board to advance iPSC-derived cell therapy pipeline and strategic growth.
Irina Ishak joins Tonix to lead legal, governance, and compliance functions starting Dec 8, 2025
Idorsia’s innovative insomnia treatment wins inaugural Prix Galien Bridges Award for Best Biotechnology & Pharmaceutical Product.
Chugai establishes a U.S. partnering office in South San Francisco to boost global innovation, deepen academic and start-up collaborations.
Roche reports Phase III data showing giredestrant reduces risk by 30% in early ER+ breast cancer, with strong safety and distant recurrence benefits.
Kane Biotech’s revyve® Antimicrobial Wound Gel Spray receives Health Canada approval, offering a new option for managing burns, ulcers, and complex wounds.
Valneva’s Phase 2 pediatric trial shows strong one-year immunity and solid safety for the IXCHIQ® chikungunya vaccine, supporting advancement to Phase 3.
Phase 3 HER2CLIMB-05 shows TUKYSA significantly extends progression-free survival in first-line HER2+ metastatic breast cancer.
AJ1-11095 receives FDA Orphan Drug Designation for myelofibrosis, advancing new therapy options for patients with limited treatment alternatives.
Amneal’s dual-format epinephrine injection approved by FDA, supporting emergency treatment of anaphylaxis and septic shock nationwide.
VTP-1000 shows strong safety and dose-dependent effects in Phase 1 AVALON trial for celiac disease, advancing immune tolerance therapy development.
Aardvark begins Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi syndrome, starting with first patient dosed in Australia.
JASCAYD (nerandomilast) approved in China as first new therapy in 5+ years for adults with progressive pulmonary fibrosis, offering improved treatment options.
Telix collaborates with Varian to combine theranostics and external beam radiation, aiming to improve prostate cancer treatment and personalized care.
Professor Prashant Yadav appointed to lead Bio Usawa’s Global Access and Health Equity Advisory Board, advancing equitable access to medicines worldwide.
Centessa Pharmaceuticals names Mario Alberto Accardi as CEO effective January 2026. His leadership will drive the company’s orexin-focused neuroscience pipeline, including OX2R agonists for narcolepsy, idiopathic hypersomnia, and broader neurological disorders.
Kymera receives FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis.
Abeona Therapeutics designates UTMB as a new Qualified Treatment Center for ZEVASKYN, the FDA-approved autologous gene therapy for recessive dystrophic epidermolysis bullosa. The partnership expands patient access across Texas and the Gulf Coast and supports advanced care for individuals living with this severe genetic skin disorder.
MAIA Biotechnology has begun dosing patients in the THIO-104 Phase 3 pivotal trial evaluating ateganosine plus a checkpoint inhibitor for advanced NSCLC. The global study compares overall survival against standard chemotherapy and builds on promising earlier data, positioning ateganosine as a potential new standard of care.
OKYO Pharma released new Phase 2 findings showing that urcosimod not only reduces neuropathic corneal pain but also improves corneal nerve structure. Patients receiving 0.05% urcosimod demonstrated increases in nerve fiber count and length, supporting its promise as a first-in-class therapy for NCP.
DISCO Pharmaceuticals appointed Mark Manfredi, Ph.D., as CEO and closed a €36M seed financing round to accelerate its surfaceome-guided ADC programs for SCLC and MSS-CRC. The funding supports IND-enabling studies, pipeline expansion, and continued development of novel oncology therapeutics driven by DISCO’s proprietary discovery platform.
BrandManthan 2025 brings pharma marketing leaders together in Mumbai to explore patient-centric branding, AI, data-driven strategy, and brand excellence awards.
FDA accepts CUTX-101 NDA resubmission for Menkes disease, advancing pediatric treatment with a target action date of January 14, 2026.
InnoCare achieves Phase 2b success for orelabrutinib in lupus and gains China approval to start Phase 3 trial, advancing Zenas BioPharma’s autoimmune pipeline.
Abeona names Mohamad Tabrizi as Chief Business Officer to lead strategy, business development, and enhance operational efficiency.
PharmAla partners with UK manufacturer to produce ALA-002, advancing its novel MDMA therapy toward Phase 2 trials in 2026.
Belgium approves BetaGlue’s clinical trial for YntraDose in unresectable pancreatic cancer, following UK and Italy clearances.
Adaptive Biotechnologies signs two non-exclusive deals with Pfizer to advance T-cell receptor research and AI-driven drug discovery.
The FDA approves Enhertu with pertuzumab for first-line HER2-positive metastatic breast cancer based on strong Phase III DESTINY-Breast09 results.
Hikma Pharmaceuticals announces CEO Riad Mishlawi’s exit as Said Darwazah assumes CEO role with immediate effect.
Thermo Fisher introduces next-generation Gibco Bacto CD media to simplify E. coli bioprocessing and improve plasmid DNA and protein yields.
Medicus completes enrolment in a Phase 2 U.S. study of D-MNA microneedle therapy for nodular basal cell carcinoma, with topline data expected in 2026.
Glenmark secures exclusive rights to develop and commercialise Hansoh’s aumolertinib across key global markets for EGFR-mutated NSCLC.
The EU approves AstraZeneca’s Saphnelo for subcutaneous self-administration in SLE, supported by positive Phase III TULIP-SC data.
Tonix acquires global rights to TNX-4900, a Sigma-1 receptor antagonist showing durable analgesic effects in neuropathic pain models.
Monte Rosa reports durable PSA and RECIST responses with MRT-2359 plus enzalutamide in AR-mutant metastatic prostate cancer.
ImmunityBio reports long-term survival, progression control and cystectomy avoidance with ANKTIVA plus BCG in papillary NMIBC patients.
Clearmind Medicine completes patient enrollment for Phase I/IIa CMND-100 trial, advancing a novel oral therapy for Alcohol Use Disorder.
Brooke Story joins PolyPid as Board Chairman, bringing 25+ years of global surgical and infection prevention leadership to guide clinical and commercial growth.
Recludix Pharma receives FDA clearance to start Phase 1 testing of REX-8756, a novel oral STAT6 inhibitor for inflammatory diseases.
Cellectar partners with Ionetix to ensure Ac-225 and At-211 supply for targeted alpha therapy programs and future clinical development.
Beacon starts LANDSCAPE trial to evaluate bilateral safety of laru-zova gene therapy for X-linked retinitis pigmentosa patients.
Chugai Pharmaceutical is named to CDP’s Double A-List, recognizing strong climate and water stewardship and transparent environmental disclosure.
EV-304 trial shows PADCEV plus Keytruda significantly improves event-free and overall survival in muscle-invasive bladder cancer.
HUTCHMED announces global Phase I clinical development of HMPL-A251, a first-in-class antibody-targeted therapy for HER2-expressing cancers.
Moleculin Biotech reports positive early Phase 1 data for WP1066 in children with aggressive brain tumors, showing immune activation and safety.
Nuvectis Pharma begins a Phase 1b trial evaluating oral NXP900 in combination with osimertinib for patients with EGFR-mutated NSCLC.
Processa reports Phase 2 data showing NGC-Cap increases capecitabine metabolite exposure without added toxicity in breast cancer patients.
Structure Therapeutics initiates a first-in-human Phase 1 trial of ACCG-2671, an oral small molecule amylin receptor agonist for obesity.
Tiziana Life Sciences doses first patient in a Phase 2 study of intranasal foralumab for early Alzheimer’s disease.
Eli Lilly reports positive Phase 3 data showing oral GLP-1 orforglipron maintains weight loss after Wegovy or Zepbound therapy.
Nxera Pharma regains full rights to its GPR52 agonist schizophrenia program after Boehringer Ingelheim declines license option.
Novo Nordisk submits an FDA NDA for once-weekly CagriSema, a GLP-1 and amylin combination injectable for obesity and overweight.
Salarius Pharmaceuticals plans to rename as Decoy Therapeutics and adopt NASDAQ ticker DCOY following its recent merger.
Thermo Fisher enrolls the first patient in its PPD CorEvitas Alzheimer’s Disease Registry to generate global real-world evidence.
Takeda reports positive topline Phase 3 data for oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque psoriasis.
vTv Therapeutics submits a Phase 2 study protocol for cadisegliatin, an oral adjunct to insulin, to DOH Abu Dhabi.
Sangamo starts a rolling BLA submission to the FDA seeking accelerated approval of ST-920 gene therapy for adults with Fabry disease.
Biofrontera completes the transfer of FDA NDA and IND approvals for Ameluz and the RhodoLED Lamp Series, gaining full U.S. control.
Alvotech and Teva settle with Regeneron, setting a U.S. launch date for AVT06, a proposed biosimilar to Eylea, in late 2026.
Cartesian Therapeutics appoints Adrian Bot, MD, PhD, to its Board, strengthening leadership in cell and immune therapy development.
ErlySign completes a 1,000-patient clinical trial for India’s first salivary biomarker test for early oral cancer detection, targeting market launch by April 2026.
Mumbai Biocluster and ICT Mumbai announce Biologics X 3DCC Summit 2026, uniting biologics and 3D cell culture leaders to advance next-gen biopharma innovation.
Japan’s MHLW approves Dupixent to treat severe or refractory asthma in children aged 6 to 11 years, expanding its pediatric use.
Alvotech begins the European launch of Gobivaz, the world’s first biosimilar to Simponi, commercialized with Advanz Pharma.
Curium announces first patient doses of PYLCLARI in Poland, expanding access to advanced PSMA PET imaging for prostate cancer.
FDA approves Amneal and mAbxience BLAs for Boncresa and Oziltus, two denosumab biosimilars to Prolia and XGEVA.
FDA approves Novo Nordisk’s oral Wegovy pill, the first oral GLP-1 for weight loss and cardiovascular risk reduction.
FDA approves AQVESME, an oral PK activator, to treat anemia in adults with alpha- or beta-thalassemia, including TD and NTDT.
Akari Therapeutics starts GMP manufacturing of AKTX-101 with WuXi XDC to support IND-enabling work ahead of Phase 1 trials.
European Commission approves Wayrilz, a novel oral BTK inhibitor, for adult patients with refractory immune thrombocytopenia.
Dyne Therapeutics names rare disease commercial leader Vikram Karnani to its Board as the company advances toward commercialization.
Pelthos Therapeutics names finance veteran Andrew Einhorn to its Board, strengthening capital markets and governance expertise.
Vor Biopharma appoints Andrew Levin of RA Capital and Wouter Joustra of Forbion to its Board following a $150 million PIPE financing.
Sanofi will acquire Dynavax for $2.2B, adding HEPLISAV-B and a shingles vaccine candidate to expand its adult immunization portfolio.
FDA issues a complete response letter for Sanofi’s tolebrutinib NDA for non-relapsing secondary progressive multiple sclerosis.
China’s NMPA approves neffy 2 mg, an epinephrine nasal spray, for emergency treatment of allergic reactions including anaphylaxis.
China’s NMPA accepts and grants priority review to HUTCHMED’s NDA for fanregratinib in FGFR2-positive ICC.
FDA grants Breakthrough Therapy Designation to ulixacaltamide for essential tremor, supporting accelerated development and review.
SELLAS reports an update on its Phase 3 REGAL trial evaluating GPS as maintenance therapy in AML patients in second remission.
Theriva receives EMA CHMP scientific advice supporting a Phase 3 trial design for VCN-01 in metastatic pancreatic cancer
Genelux names Jason Litten, MD, as Chief Medical Officer to lead clinical development as Olvi-Vec advances toward key milestones.
HUTCHMED begins the Phase III stage of its Phase II/III trial evaluating a four-drug combination as first-line therapy for metastatic PDAC.
ELMACH highlights the WKH-100 intermittent motion cartoner, offering flexible, GMP-compliant cartoning for pharma and cosmetics.
Biodexa Pharmaceuticals appoints Fiona Sharp as Chief Financial Officer and Company Secretary, and elects her to the Board.
ElevateBio names biopharma veteran Christopher Murphy as CEO and Board member to lead the company’s next growth phase.
Kriya Therapeutics names Sachiyo Minegishi as Chief Financial Officer to support corporate strategy and gene therapy commercialization plans.
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO, as Gary Jacob transitions to Chief Development Officer.
Tango Therapeutics names finance leader Sung Lee to its Board as the company advances vopimetostat into registrational studies.
Discover drug safety symposium Dubai highlights expert sessions and pharmacovigilance insights shaping patient safety regulatory and risk management trends in the pharma industry.
Explore highlights from Remarkable Women Awards 2026 celebrating pharmaceutical leadership innovation empowerment and women changemakers shaping the industry future.
Explore highlights from Remarkable Women Goa 2026 Awards celebrating leadership empowerment networking and recognition of women shaping change across industries and communities.
Atsena Therapeutics names McDavid Stilwell CFO to support gene therapy development and its LIGHTHOUSE trial for inherited retinal disease.
Galecto names Sherwin Sattarzadeh COO and Dr. Becker Hewes CMO to advance its pipeline toward clinical trials.
Remix Therapeutics names Mythili Koneru, MD, PhD, as CMO to lead clinical development of its RNA-targeting pipeline.
Sparrow Pharmaceuticals enrolls first patient in the Phase 2b CAPTAIN-T2D trial evaluating clofutriben in difficult-to-control type 2 diabetes.
SpyGlass Pharma names Jean-Frédéric Viret CFO to support late-stage development and commercialization of its BIM-IOL System.
Ascentage Pharma receives FDA IND clearance for APG-3288, enabling Phase 1 trials in relapsed or refractory B-cell malignancies.
Jazz Pharmaceuticals reports positive Phase 3 HERIZON-GEA-01 results for Ziihera, showing significant PFS and OS benefit in HER2+ GEA.
Outlook Therapeutics names Laura Cantrell VP of Corporate Strategy and Business Development to support long-term growth initiatives.
EMA accepts Milestone Pharma’s MAA for etripamil nasal spray, a self-administered treatment for paroxysmal SVT.
Thermo Fisher enrolls first patient in the PPD CorEvitas Obesity Registry to generate real-world evidence on obesity management.
Jasper Therapeutics names Jeet Mahal as President and CEO as it prepares to advance briquilimab into registrational trials for CSU.
Onco360 is named a limited distribution specialty pharmacy partner for Rigel’s TAVALISSE, GAVRETO, and REZLIDHIA.
FDA clears IND for Ottimo Pharma’s OTP-01, with first patient dosed in Phase I/IIA solid tumor study.
Crohn’s & Colitis Foundation approves up to $500K equity investment in Palisade Bio to advance PALI-2108.
Sanara MedTech’s BIASURGE solution secures a Vizient Innovative Technology contract, expanding access across U.S. hospitals.
Turn Therapeutics adds life sciences veteran Martin Dewhurst to its Board to support M&A-driven growth strategy.
Vaxxas names former Merck Global Vaccines President David Peacock as CEO to lead HD-MAP vaccine commercialization.
Syndax partners with WODA to expand international patient access to Revuforj through a global Managed Access Program.
Monte Rosa shares positive interim Phase 1 data for MRT-8102, showing strong inflammation reduction and favorable safety.
Merck launches Phase 3 KANDLELIT-007 trial evaluating calderasib plus KEYTRUDA QLEX in KRAS G12C-mutant NSCLC.
Merck completes its cash tender offer to acquire Cidara Therapeutics, strengthening its respiratory pipeline with CD388.
AstraZeneca names Joris Silon as Head of Investor Relations, effective March 2026, succeeding Andy Barnett and strengthening global investor engagement.
Amylyx names AMX0318, a long-acting GLP-1 receptor antagonist, as a development candidate for post-bariatric hypoglycemia and rare diseases.
Takeda signs global deal with Halozyme to use ENHANZE technology with vedolizumab, aiming to improve treatment flexibility for IBD patients.
Ascendis Pharma reports positive Week 52 Phase 2 data for once-weekly TransCon CNP and hGH combination in pediatric achondroplasia.
MUSC Health and Baxter announce a multi-year partnership to advance connected care, nursing workflows, and patient safety.
FDA grants Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutated NSCLC after prior therapy.
Catalyst Pharmaceuticals ranks 11th on Forbes’ 2026 list of America’s Most Successful Small-Cap Companies.
Dewpoint Therapeutics selects a first-in-class TDP-43 development candidate targeting ALS and related neurodegenerative diseases.
Tango Therapeutics announces CEO transition as Barbara Weber retires and Malte Peters steps in to lead the next growth phase.
Polyrizon finalizes NASARIX™ branding for its PL-14 intranasal allergy blocker ahead of future clinical and commercial steps.
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer to lead corporate development and strategic partnerships starting January 2026.
Nxera Pharma licenses vamorolone from Santhera to develop and commercialize the DMD therapy across Japan, South Korea, Australia, and New Zealand.
Alps Group names Cheing Lye-Ping as CFO to lead financial strategy as the company enters its next phase of growth and innovation.
CorMedix extends CEO Joseph Todisco’s contract, names him Chairman, appoints Mike Seckler as Chief Commercial Officer.
Pharmapack 2026 returns to Paris on Jan 21–22, uniting global leaders in pharma packaging and drug delivery innovation.
Benitec shares long-term Phase 1b/2a data showing sustained, disease-modifying benefits of BB-301 in OPMD patients.
Royalty Pharma and Teva enter up to $500M funding deal to advance TEV-408, an anti-IL-15 antibody for autoimmune diseases.
Achieve Life Sciences promotes Mark Rubinstein, MD, to Chief Medical Officer as cytisinicline advances toward regulatory review.
Biocartis collaborates with Mayo Clinic to develop a rapid, sample-to-answer breast cancer test to speed treatment decisions.
European Commission approves Biogen’s high-dose SPINRAZA regimen, enabling faster loading and expanded dosing options for SMA patients.
Disc Medicine names Lisa Amaya Price as Chief Human Resources Officer to support organizational growth ahead of commercialization.
Gradalis names Steven D. Weinstein as CEO to lead its personalized cancer immunotherapy platform into the next phase of growth.
AbbVie will acquire West Pharmaceutical’s Tempe device facility to expand drug delivery manufacturing capacity and strengthen pharmaceutical production capabilities in the US.
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.
Medicus Pharma’s Teverelix Phase 1 data accepted at AACE 2026, showing rapid, reversible hormone suppression with favorable safety.
BioMarin names Arpit Davé as EVP and Chief Digital and Information Officer to lead AI, data, and enterprise digital transformation.
Thermo Fisher Scientific collaborates with NVIDIA to integrate AI and automation, accelerating research efficiency and lab innovation.
Amneal Pharmaceuticals launches a new brand identity reflecting its evolution into a diversified global biopharma company.
AbbVie agrees to lower Medicaid drug prices and invest $100B in U.S. R&D under a voluntary federal agreement.
Aligos Therapeutics names James Hassard as EVP and Chief Commercial Officer to strengthen commercial readiness ahead of late-stage development.
FDA approves ZYCUBO, the first U.S. treatment for Menkes disease, marking a major milestone for Fortress Biotech and Cyprium.
FDA grants Breakthrough Therapy Designation to Ipsen’s IPN60340 combo for first-line treatment of unfit AML patients.
Pelthos Therapeutics names finance veteran Andrew Einhorn to its Board, strengthening capital markets and governance expertise.
ImmunityBio shares encouraging QUILT trial data showing immune restoration and survival benefit with ANKTIVA in NSCLC patients.
Baxter unveils its Dynamo Series smart stretcher, designed to ease clinician workload and enhance patient safety and connectivity.
Shuttle Pharmaceuticals supports Utah’s AI refill pilot and highlights Molecule.ai to reduce drug discovery time, cost, and failure risk.
Praxis Precision Medicines names epilepsy leader Dr. Orrin Devinsky to guide late-stage CNS programs toward commercialization.
STEERLife’s FragMelt™ platform helps BionPharma secure USFDA approval for generic Etravirine, advancing sustainable HIV drug manufacturing.
Clearmind Medicine reports all patients in second cohort of Phase I/IIa CMND-100 trial for AUD have successfully completed treatment.
Oncolytics strengthens leadership with new EVP of Strategy and VP of Biostatistics to advance pelareorep registration programs.
Hikma secures B ratings for Climate Change and Water Security in CDP 2025, reflecting stronger governance and progress in sustainability reporting.
GT Biopharma submits FDA IND for GTB-5550, a B7-H3–targeted TriKE NK cell engager, advancing toward Phase 1 solid tumor trials.
Ocugen reports encouraging 12-month Phase 2 data for OCU410, showing reduced lesion growth in geographic atrophy from dry AMD.
Valneva voluntarily withdraws U.S. BLA and IND filings for its chikungunya vaccine IXCHIQ following FDA suspension and safety review.
China’s NMPA has accepted Telix’s NDA for Illuccix, expanding access to PSMA-PET imaging for prostate cancer backed by Phase 3 data.
Hikma launches Enoby and Xtrenbo in the US, expanding access to denosumab biosimilars for osteoporosis and cancer-related bone disease.
Nxera Pharma reports positive Phase 3 results for daridorexant in South Korea and plans regulatory filing in Q1 2026.
MediPharm Labs appoints CFO Greg Hunter as Interim CEO following David Pidduck’s decision to step down in January 2026.
Concept Life Sciences names Dr Adam Davenport as Chief Scientific Officer to strengthen its integrated drug discovery capabilities.
Manthan 2026 R&D Leadership Symposium brought India’s life sciences leaders together to shape the future of research and innovation.
BrightInsight adds senior executives to its leadership team to support global expansion, AI-driven digital health platforms, and biopharma partnerships.
Capricor prepares full HOPE-3 clinical study report for FDA as part of ongoing BLA review for Deramiocel in Duchenne MD.
BrightInsight secures $13M funding to accelerate AI-powered digital health solutions improving medication adherence and persistence.
Novo Nordisk and Aspect Biosystems advance their partnership to develop next-generation cell therapies for diabetes and type 1 diabetes.
Rentschler Biopharma appoints Uwe Buecheler as interim CEO as part of a leadership transition to support long-term growth strategy.
EMA grants orphan drug designation to Rein Therapeutics’ LTI-03, supporting its development for idiopathic pulmonary fibrosis.
Peptinovo Biopharma receives ethics approval in Australia to begin first-in-human clinical trials using PALM™ cancer therapy.
GSK to acquire RAPT Therapeutics, adding Phase IIb anti-IgE antibody ozureprubart to its immunology pipeline.
Moderna and Merck report durable 5-year data for personalized mRNA therapy plus KEYTRUDA in high-risk melanoma.
Bristol Myers Squibb partners with Microsoft to deploy AI-powered radiology tools for earlier lung cancer detection in the U.S.
Corvus Pharmaceuticals reports strong Phase 1 results for soquelitinib in moderate-to-severe atopic dermatitis.
ImmunityBio Meets FDA on ANKTIVA sBLA Expansion
Nxera Pharma establishes a global Metabolic Advisory Council to guide next-generation obesity and metabolic programs.
Crystalys Therapeutics names biotech finance veteran Justin Thacker as CFO as it advances dotinurad into global Phase 3 gout trials.
Charles River and Gazi University collaborate to advance gene therapy research for a rare phosphate disorder using AAV plasmids.
ARS Pharma adds California to its neffyinSchools program, expanding access to needle-free epinephrine nasal spray for school emergencies.
Aligos outlines interim analysis timelines for its Phase 2 B-SUPREME study evaluating pevifoscorvir sodium in chronic HBV patients.
FDA approves use of Greenwich LifeSciences’ first commercial GP2 lot in the Phase III FLAMINGO-01 breast cancer trial.
BioStem expands its advanced wound care portfolio by acquiring BioTissue’s surgical and wound care business and product lines.
Medicus Pharma lowers global royalty rate for Teverelix to 2% after amending its licensing agreement with LifeArc.
NKGen Biotech adds renowned neurologist Dr. Bruce L. Miller to its Scientific Advisory Board to support Alzheimer’s and FTD programs.
Pharmapack announces Pharmapack Asia 2026, launching in Singapore in November 2026 to expand its global pharma packaging footprint.
Pharma Now Podcast features Abhay Kumar Srivastava of Mankind Pharma on Lean manufacturing, quality culture, and ops excellence.
Akari Therapeutics files a US patent for AKTX-102, a first-in-class CEACAM5-targeted ADC using its PH1 RNA-splicing payload.
FDA grants Breakthrough Therapy Designation to Cogent’s bezuclastinib plus sunitinib for imatinib-resistant GIST patients.